Descrizione

In vivo tumor growth data from xenograft models comparing melatonin-treated and control groups. Tumor volume measurements suggest MLT suppresses prostate cancer growth.

Figure 18

Chart

Source Paper

Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.

Clinical and translational medicine (2021)

PMID: 34185414

DOI: 10.1002/ctm2.449

Cite This Figure

![Figure 18: In vivo tumor growth data from xenograft models comparing melatonin-treated and control groups. Tumor volume measurements suggest MLT suppresses prostate cancer growth.]()

> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)

<figure>
  <img src="" alt="In vivo tumor growth data from xenograft models comparing melatonin-treated and control groups. Tumor volume measurements suggest MLT suppresses prostate cancer growth." />
  <figcaption>Figure 18. In vivo tumor growth data from xenograft models comparing melatonin-treated and control groups. Tumor volume measurements suggest MLT suppresses prostate cancer growth.<br>  Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption>
</figure>

Evidenze correlate

Melatonin per Disturbo del ritmo circadiano

Grado A · 176 studi